BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, November 27, 2024
Breaking News: Healing a health divide (that’s long overdue)
See today's BioWorld Science
Home
» SYS-6002 receives clinical trial approval in China
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Immuno-oncology
SYS-6002 receives clinical trial approval in China
Oct. 28, 2022
No Comments
CSPC Pharmaceutical Group Ltd. announced that the National Medical Products Administration of the People’s Republic of China has granted approval to conduct clinical trials of the company’s antibody-drug conjugate candidate, SYS-6002.
BioWorld Science
Cancer
Antibody-drug conjugate
Immuno-oncology
NMPA
